Your session is about to expire
← Back to Search
ATR + PARP Inhibitors for Prostate Cancer
Study Summary
This trial will test a new combination of drugs to treat prostate cancer that has spread and is resistant to hormone therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am on hormone therapy for cancer and my testosterone is very low.My cancer has grown or spread, as shown by recent scans.Your PSA levels have been continuously increasing for at least a week and started at a minimum of 1.0 ng/mL.I have taken medication like abiraterone for my cancer, but it's still getting worse.I can swallow pills and don't have serious stomach or bowel issues affecting medication absorption.I don't have active brain cancer, but if I had it before, it's now stable and I've finished all treatments for it over 3 weeks ago.I've had treatment for prostate cancer that's now resistant to hormone therapy.I agree to a biopsy for DNA repair status, or I have prior DNA sequencing results.I have had episodes of fainting or near-fainting not caused by reversible reasons.I agree to use barrier contraception during the study and for some time after.My high blood pressure is severe and needs quick medication changes.I have been diagnosed with ataxia telangiectasia.Your doctor thinks you will live for at least 16 more weeks.I haven't had any cancer except for skin cancer or early bladder cancer in the last 3 years.It has been over 21 days since my last palliative radiation, except for certain types where it's been over 28 days.I have or had myelodysplastic syndrome or acute myeloid leukemia.I haven't taken certain cancer drugs for at least 21 days or 5 half-lives before starting the new treatment.I had major surgery more than 2 weeks ago and have recovered.I have stopped taking certain medications that affect liver enzymes as required before starting treatment.I stopped my previous cancer therapy 3 weeks ago but may still be on prednisone.I am not allergic to olaparib, AZD6738, or their ingredients.My cancer has worsened despite low testosterone and previous treatments.I have not had serious heart issues in the last 6 months.My prostate cancer has spread, as shown on scans.My blood, liver, and kidney functions are within normal ranges as tested recently.I have not had a live vaccine in the last 2 weeks.I haven't had a whole blood transfusion in the last 4 months.I have had a bone marrow or cord blood transplant in the past.I have previously been treated with drugs targeting DNA repair.I don't have lasting side effects from cancer treatment, except for hair loss or mild nerve pain.I have been mostly active and able to carry out all my pre-disease activities up to 42 days before signing up.I am a man aged 18 or older.My prostate cancer is confirmed not to be small-cell or neuroendocrine type.I am willing and able to follow the study's requirements, including biopsies, treatments, and visits.I have received one treatment for metastatic castration-resistant prostate cancer.My heart's electrical activity is normal and I don't have low blood pressure or sudden drops when standing.You must agree to participate in the study before any procedures can be done.
- Group 1: Cohort 1 (DRPro)
- Group 2: Cohort 2 (DRDef)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment a new endeavor?
"Since its initial study in 2005, sponsored by AstraZeneca and involving 98 participants, AZD6738 has been trialed extensively. Ultimately leading to Phase 1 drug approval, there are now 199 active trials for this medication across 59 nations and 1472 cities."
How many participants are engaged in this experiment?
"At this time, the clinical trial is not open for enrollment. It was originally published on October 31st 2019 and last edited on July 18th 2022. For those seeking alternative studies, there are 1315 trials actively recruiting prostate cancer participants and 199 involving AZD6738 that have opened their doors to volunteers."
What medical conditions have been found to be treatable with AZD6738?
"AZD6738 is a potential medication for those facing advance directives, malignant neoplasm of the ovary or primary peritoneal cancer."
To what degree is AZD6738 a safe intervention for patients?
"With only preliminary data regarding its safety, AZD6738 received a score of 2. There is currently no evidence suggesting it's efficacy."
Has AZD6738 been subject to other research projects?
"At present, 199 scientific investigations are being conducted into AZD6738 with 27 of those studies in the advanced Phase 3. Although Houston is the main hub for researching this therapy, there are a total of 9407 locations running experiments on it."
Are there currently any open slots for participants in this clinical research?
"Clinicaltrials.gov data confirms that this specific trial is not currently recruiting patients, as the last modification was made on July 18th 2022. However, there are 1,514 alternative studies actively enrolling participants at present."
Share this study with friends
Copy Link
Messenger